Women with pathogenic germline mutations in cancer susceptibility genes — that is, in BRCA1 or BRCA2 (BRCA1/2) — may opt to undergo prophylactic bilateral mastectomy; primary chemoprophylaxis with tamoxifen or other selective oestrogen receptor modulators has also been recommended in this group, albeit the uptake is low16. This evidence concerns the gene BRCA1 and cancer.